Kurt Von Emster Sells 211,124 Shares of CymaBay Therapeutics Inc. (CBAY) Stock
CymaBay Therapeutics Inc. (NASDAQ:CBAY) Director Kurt Von Emster sold 211,124 shares of the business’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $8.09, for a total value of $1,707,993.16. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
CymaBay Therapeutics Inc. (CBAY) opened at 7.67 on Wednesday. The stock’s market cap is $335.61 million. CymaBay Therapeutics Inc. has a 52 week low of $1.15 and a 52 week high of $8.45. The company has a 50-day moving average price of $6.85 and a 200-day moving average price of $5.44.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.06). Equities research analysts anticipate that CymaBay Therapeutics Inc. will post ($0.82) EPS for the current year.
A number of research firms have commented on CBAY. Oppenheimer Holdings, Inc. began coverage on CymaBay Therapeutics in a research note on Friday, June 23rd. They issued an “outperform” rating and a $8.00 price target for the company. Cantor Fitzgerald started coverage on CymaBay Therapeutics in a report on Tuesday, September 19th. They issued an “overweight” rating and a $16.00 price target for the company. Zacks Investment Research upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Ifs Securities lowered CymaBay Therapeutics from a “strong-buy” rating to an “outperform” rating in a research note on Friday, August 11th. Finally, SunTrust Banks, Inc. assumed coverage on shares of CymaBay Therapeutics in a report on Friday, August 18th. They set a “buy” rating and a $15.00 price objective on the stock. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $12.69.
Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in shares of CymaBay Therapeutics by 0.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 140 shares in the last quarter. ClariVest Asset Management LLC purchased a new position in shares of CymaBay Therapeutics in the 1st quarter valued at $105,000. LVM Capital Management Ltd. MI grew its position in shares of CymaBay Therapeutics by 100.0% in the 2nd quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 10,000 shares during the last quarter. Marshall Wace North America L.P. purchased a new position in shares of CymaBay Therapeutics in the 2nd quarter valued at $242,000. Finally, Ardsley Advisory Partners grew its position in shares of CymaBay Therapeutics by 66.2% in the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 25.91% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Stock Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related stocks with our FREE daily email newsletter.